Who are Single-Dose IV Oritavancin Diphosphate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oritavancin Injection, Dalbavancin via Intravenous Administration, Dalbavancin via Intraperitoneal Administration, Dalbavancin administration, IV Dalbavancin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/single-dose-iv-oritavancin-diphosphate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Single-Dose IV Oritavancin Diphosphate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single-Dose IV Oritavancin Diphosphate (Single-Dose IV Oritavancin Diphosphate) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipoglycopeptide antibiotic. Area: Infectious Diseases.

phase 3 Lipoglycopeptide antibiotic Lipid II Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Single-Dose IV Oritavancin Diphosphate (Single-Dose IV Oritavancin Diphosphate) — Melinta Therapeutics, Inc.. Oritavancin diphosphate is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Single-Dose IV Oritavancin Diphosphate TARGET	Single-Dose IV Oritavancin Diphosphate	Melinta Therapeutics, Inc.	phase 3	Lipoglycopeptide antibiotic	Lipid II
Oritavancin Injection	Oritavancin Injection	University of Pennsylvania	marketed	Lipoglycopeptide antibiotic	Bacterial peptidoglycan precursors (D-Ala-D-Ala) and lipid II
Dalbavancin via Intravenous Administration	Dalbavancin via Intravenous Administration	University of Colorado, Denver	marketed	Lipoglycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursors
Dalbavancin via Intraperitoneal Administration	Dalbavancin via Intraperitoneal Administration	University of Colorado, Denver	marketed	Lipoglycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Dalbavancin administration	Dalbavancin administration	Assistance Publique - Hôpitaux de Paris	phase 3	Lipoglycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
IV Dalbavancin	IV Dalbavancin	Durata Therapeutics Inc., an affiliate of Allergan plc	phase 3	Lipoglycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipoglycopeptide antibiotic class)

University of Colorado, Denver · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Durata Therapeutics Inc., an affiliate of Allergan plc · 1 drug in this class
Melinta Therapeutics, Inc. · 1 drug in this class
University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Single-Dose IV Oritavancin Diphosphate — Competitive Intelligence Brief. https://druglandscape.com/ci/single-dose-iv-oritavancin-diphosphate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab